Latest News
Ferring Gameto Acquisition: What Does Ferring Get From the Deal?
The Ferring Gameto acquisition would give Ferring Pharmaceuticals control of Fertilo, Gameto’s lead investigational fertility programme. Fertilo is derived from induced pluripotent stem cells and is designed to mature eggs outside the body. Ferring and Gameto...
Latest News
How AI Is Redefining the Modern Healthcare Consultation
Healthcare in the United States is facing a structural inflection point. Physician burnout remains high. Administrative burdens consume hours that should be spent with patients. Chronic disease rates continue to rise. At the same time, health systems are under...
I’m a Black Gestational Carrier. How People Calculate My Risk Is Wrong
Adding Black maternal-health statistics to data on gestational carriers and calling the sum mine doesn't make it so. The numbers don’t work that way. I’ve carried three pregnancies for other families. I’m also a Black woman. Put those facts beside two well-documented...
Disease Progression Slowing Holds on Function, Misses on Composite
uniQure released four-year results for its Huntington’s disease gene therapy on Tuesday 29 September 2026. The disease progression slowing measured on the composite clinical scale narrowed at 48 months. It missed statistical significance. A second measure, Total...
The Writing Got Cheap. The Checking Did Not
Last month I published a cost analysis with wrong numbers in it. Not rounded wrong. I had taken the wrong price list and the wrong tariff for cache writes, and when I recomputed, the headline figure moved. I issued a corrected version and stopped citing the first one....
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
How AI-Enabled Functional Precision Oncology Is Personalizing Treatment
When the Standard Playbook Runs Out In pediatric and adult oncology alike, there is a recognizable moment when the standard treatment playbook is exhausted. For patients with rare, relapsed, or treatment-resistant cancers, guidelines built for the common case offer...
The Infrastructure Gap Behind the GLP-1 Boom
The rapid rise of GLP-1 medications has transformed healthcare delivery in ways few therapeutic categories have achieved in recent decades. Originally developed to help manage type 2 diabetes, GLP-1 receptor agonists such as semaglutide and tirzepatide have become...
How Climate Change is Redrawing Europe’s Disease Landscape
The impact of climate change is usually discussed in terms of heatwaves and floods. While less visible, its impact on infectious diseases is equally consequential for public health. New data from the UK Health Security Agency (UKHSA) showing a surge in chikungunya...
A Path to Rebuilding American Manufacturing for Lab Consumables
Amid today's geopolitical tensions, supply chain vulnerability is emerging as an increasingly central concern, and, in the case of life science consumables, one that places the health of the public at risk. The issue itself, however, is far from new. In December 2020...
Weekly News Roundup | 13 July 2026
Life science news 13 July 2026: Vertex seals a $10 billion deal for rare endocrine specialist Crinetics, the FDA clears the first dual BAFF/APRIL inhibitor for IgA nephropathy, and Novartis acquires a UK cancer therapy spinout in a blockbuster week for pharma, biotech...
Medicare GLP-1 Bridge: Who Qualifies and Who Does Not
The Medicare GLP-1 Bridge launched on 1 July 2026, opening a new pathway for eligible Medicare Part D beneficiaries to access weight management medications at a fixed monthly copay of $50. For clinicians navigating GLP-1 Bridge eligibility criteria, the prior...
The Next Public Health Playbook: Why Trust Matters More Than Ever
The current news cycle is dominated by new and exotic-sounding organisms and chemicals: PFOS, bisphenols, phthalates, Mpox, New World screwworm, Andes hantavirus, Ebola bundibugyo, Borrelia burgdorferi, dengue, and chikungunya. What do they have in common? They are...
Clinical Trials Roundup | 10 July 2026
Roche’s divarasib demonstrates superiority over approved KRAS G12C inhibitors in the Phase 3 Krascendo 1 head-to-head lung cancer trial, Vera Therapeutics’ Trutakna receives FDA accelerated approval as the first BAFF/APRIL inhibitor for IgA nephropathy, Rhythm...
Adipose Tissue Isn’t Just Storage: Fat as an Endocrine and Immune Organ
For much of the 20th century, body fat was viewed mainly as the body's energy reservoir—a passive tissue that stored excess calories for future use. While this remains an important function of adipose tissue, research over the past few decades has revealed a far more...
FDA Drug Approval Decisions to Watch: July and August 2026
The second half of 2026 is shaping up to be one of the most consequential periods for FDA drug approval decisions in recent memory. Between mid-July and late August, the US Food and Drug Administration faces a succession of Prescription Drug User Fee Act target action...
New Research On the Next Phase in Protecting Muscle During GLP-1 Treatment
When I wrote previously for this publication about the gap between GLP-1 prescribing rates and the clinical conversation around lean muscle preservation, the argument centred on a simple premise: weight loss is not fat loss, and the clinical infrastructure around...
Atacicept FDA Approval: Trutakna Cleared for IgAN
The atacicept FDA approval that the nephrology community had been anticipating since January arrived on schedule on 7 July 2026, when the US Food and Drug Administration granted accelerated approval to Vera Therapeutics' atacicept-vymj, to be marketed as Trutakna, for...
How AI-Enabled Functional Precision Oncology Is Personalizing Treatment
When the Standard Playbook Runs Out In pediatric and adult oncology alike, there is a recognizable moment when the standard treatment playbook is exhausted. For patients with rare, relapsed, or treatment-resistant cancers, guidelines built for the common case offer...
The Infrastructure Gap Behind the GLP-1 Boom
The rapid rise of GLP-1 medications has transformed healthcare delivery in ways few therapeutic categories have achieved in recent decades. Originally developed to help manage type 2 diabetes, GLP-1 receptor agonists such as semaglutide and tirzepatide have become...
How Climate Change is Redrawing Europe’s Disease Landscape
The impact of climate change is usually discussed in terms of heatwaves and floods. While less visible, its impact on infectious diseases is equally consequential for public health. New data from the UK Health Security Agency (UKHSA) showing a surge in chikungunya...
A Path to Rebuilding American Manufacturing for Lab Consumables
Amid today's geopolitical tensions, supply chain vulnerability is emerging as an increasingly central concern, and, in the case of life science consumables, one that places the health of the public at risk. The issue itself, however, is far from new. In December 2020...
Weekly News Roundup | 13 July 2026
Life science news 13 July 2026: Vertex seals a $10 billion deal for rare endocrine specialist Crinetics, the FDA clears the first dual BAFF/APRIL inhibitor for IgA nephropathy, and Novartis acquires a UK cancer therapy spinout in a blockbuster week for pharma, biotech...
Medicare GLP-1 Bridge: Who Qualifies and Who Does Not
The Medicare GLP-1 Bridge launched on 1 July 2026, opening a new pathway for eligible Medicare Part D beneficiaries to access weight management medications at a fixed monthly copay of $50. For clinicians navigating GLP-1 Bridge eligibility criteria, the prior...
The Next Public Health Playbook: Why Trust Matters More Than Ever
The current news cycle is dominated by new and exotic-sounding organisms and chemicals: PFOS, bisphenols, phthalates, Mpox, New World screwworm, Andes hantavirus, Ebola bundibugyo, Borrelia burgdorferi, dengue, and chikungunya. What do they have in common? They are...
Clinical Trials Roundup | 10 July 2026
Roche’s divarasib demonstrates superiority over approved KRAS G12C inhibitors in the Phase 3 Krascendo 1 head-to-head lung cancer trial, Vera Therapeutics’ Trutakna receives FDA accelerated approval as the first BAFF/APRIL inhibitor for IgA nephropathy, Rhythm...
Adipose Tissue Isn’t Just Storage: Fat as an Endocrine and Immune Organ
For much of the 20th century, body fat was viewed mainly as the body's energy reservoir—a passive tissue that stored excess calories for future use. While this remains an important function of adipose tissue, research over the past few decades has revealed a far more...
FDA Drug Approval Decisions to Watch: July and August 2026
The second half of 2026 is shaping up to be one of the most consequential periods for FDA drug approval decisions in recent memory. Between mid-July and late August, the US Food and Drug Administration faces a succession of Prescription Drug User Fee Act target action...
New Research On the Next Phase in Protecting Muscle During GLP-1 Treatment
When I wrote previously for this publication about the gap between GLP-1 prescribing rates and the clinical conversation around lean muscle preservation, the argument centred on a simple premise: weight loss is not fat loss, and the clinical infrastructure around...
Atacicept FDA Approval: Trutakna Cleared for IgAN
The atacicept FDA approval that the nephrology community had been anticipating since January arrived on schedule on 7 July 2026, when the US Food and Drug Administration granted accelerated approval to Vera Therapeutics' atacicept-vymj, to be marketed as Trutakna, for...
Featured Articles
Further News
AI Trust in Healthcare Starts with the People in the Room
Healthcare is on an accelerated path to digitisation, creating real opportunity to reduce administrative burden, improve risk detection, support prioritisation, and help people access the right care sooner. But without deliberate design, these same systems risk...
The Regulatory Window for AI in Pharmacovigilance Is Open
In more than two decades of working with global CROs, pharmaceutical companies, and biotech organizations, I have watched pharmacovigilance teams absorb wave after wave of increasing complexity. More products on the market. More data sources to monitor. More...
Webinar: Decoding Neurodegeneration via iPSC-Derived Human Brain Models
The human brain presents an intricate evolutionary paradox. While its sophisticated neural networks govern complex cognition, its architecture is uniquely susceptible to progressive degradation. For decades, the biomedical community has grappled with an uncomfortable...
Why the Immune System Is Becoming the New Battlefield in Cancer Care
The Old Paradigm For more than a century, cancer treatment has been defined by a straightforward objective: find the tumor and destroy it. Surgery removes it, radiation damages it. Chemotherapy attacks rapidly dividing cells. These approaches have saved countless...
CE Marking Is Not Enough: Three Layers for Connected Medical Devices
If your device connects to a network and runs AI, CE marking under MDR or IVDR is only the first layer for connected medical devices. Two further EU frameworks, the AI Act and the Cyber Resilience Act, can also apply, each with obligations that go beyond what MDR...
When Months Become Days: AI’s Edge in Patient Engagement
Every therapy that reaches a patient first has to clear a quieter hurdle that rarely makes headlines: finding enough of the right people to test it. That hurdle is where most clinical programs stumble. Roughly 80% of clinical trials fail to meet their enrollment...
What My Stroke Recovery Taught Me About Mobility and Safer Care
After more than three decades in nursing, I have had the privilege of caring for patients during some of the most vulnerable moments of their lives. I have worked alongside extraordinary nurses, therapists, physicians, and support staff who dedicate themselves to...
Tregzi (Orca Bio): Inside the First Regulatory T-Cell Therapy for Blood Cancer
The US Food and Drug Administration has approved Tregzi, a regulatory T-cell therapy developed by Orca Bio. It is the first treatment built from highly purified regulatory T cells to reach the American market. The FDA cleared Tregzi on 30 June 2026. It is designed to...
Workforce Capability Standardization in Medical Affairs
For decades, the pharmaceutical industry has invested heavily in scientific innovation, regulatory rigor, clinical development, manufacturing quality, and commercial excellence. Yet one of the most important links between innovation and patient impact has remained...
Weekly News Roundup | 06 July 2026
Life science news 6 July 2026: the FDA expands the world’s first CRISPR gene therapy to children as young as two, Ipsen commits up to $1.75 billion for a late-stage blood cancer drug, and two first-in-class FDA approvals reshape the cell therapy landscape in a busy...
Atacicept IgA Nephropathy: FDA Decision Due 7 July
Four days from now, the US Food and Drug Administration is due to hand down its atacicept IgA nephropathy decision, ruling on whether the experimental Vera Therapeutics drug becomes the first therapy to target both BAFF and APRIL in adults with the disease. The...
Clinical Trials Roundup | 03 July 2026
Genmab and AbbVie's epcoritamab meets its primary endpoint in a Phase 3 trial for relapsed or refractory diffuse large B-cell lymphoma, the FDA approves Orca Bio's Tregzi as the first regulatory T-cell therapy to reduce chronic graft-versus-host disease in blood...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.